InvestSMART

Arbitr Group Limited (ASX: AGT) - Announcements

Current share price for AGT : $0.097 0.003 (3%)+

ASX company news and announcements for Arbitr Group Limited (AGT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Arbitr Group Limited (AGT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Arbitr Group Limited (AGT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Arbitr Group Limited (AGT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Notification of cessation of securities - AGT 5 Nov 2026 10:21AM $0.100 $0.097 fallen by 3%
$6 Results of 2026 Annual General Meeting 4 Nov 2026 4:25PM $0.100 $0.097 fallen by 3%
$6 2026 AGM Chair's Address and CEO Presentation 4 Nov 2026 11:33AM $0.110 $0.097 fallen by 11.82%
$6 Proposed issue of securities - AGT 4 Nov 2026 9:59AM $0.110 $0.097 fallen by 11.82%
$6 Proposed issue of securities - AGT 4 Nov 2026 9:56AM $0.110 $0.097 fallen by 11.82%
$6 Proposed issue of securities - AGT 4 Nov 2026 9:43AM $0.110 $0.097 fallen by 11.82%
$6 Proposed A$4.86 Million Capital Raising and Business Update 4 Nov 2026 9:38AM $0.110 $0.097 fallen by 11.82%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2026 5:08PM $0.120 $0.097 fallen by 19.17%
$6 Notice of Annual General Meeting/Proxy Form 2 Oct 2026 10:08AM $0.125 $0.097 fallen by 22.40%
$6 Change of Company Name and ASX Code 29 Sep 2026 9:22AM n/a $0.097 n/a
$6 Positive Results for Anti-Cancer Clinical Trial 9 Jun 2004 8:30AM $0.490 $0.097 fallen by 80.20%
$6 Cross Border Merger with ChemGenex Therapeutics 27 Apr 2004 9:26AM $0.560 $0.097 fallen by 82.68%
$6 Accepted into Federal Gov. Pharmaceuticals Partnership Prog. 23 Apr 2004 4:09PM $0.520 $0.097 fallen by 81.35%
$6 Accepted into Federal Gov. Pharmaceuticals Partnership Prog. 23 Apr 2004 4:09PM $0.520 $0.097 fallen by 81.35%
$6 Half Yearly Report & Half Year Accounts 27 Feb 2004 10:15AM $0.485 $0.097 fallen by 80%
$6 Patents novel targets for over the counter obesity therapies 4 Feb 2004 9:28AM $0.560 $0.097 fallen by 82.68%
$6 Patents novel targets for over the counter obesity therapies 4 Feb 2004 9:28AM $0.560 $0.097 fallen by 82.68%
$6 AGT Biosciences Researches Attract NH & MRC Funding 22 Jan 2004 9:45AM $0.470 $0.097 fallen by 79.36%
$6 AGT Biosciences Researches Attract NH & MRC Funding 22 Jan 2004 9:45AM $0.470 $0.097 fallen by 79.36%
$6 Clinches major collaboration with US Company 20 Nov 2003 9:36AM $0.520 $0.097 fallen by 81.35%
$6 Clinches major collaboration with US Company 20 Nov 2003 9:36AM $0.520 $0.097 fallen by 81.35%
$6 Patent Protected Gene has Implications in Multiple Diseases 29 Sep 2003 9:33AM $0.610 $0.097 fallen by 84.10%
$6 Patent Protected Gene has Implications in Multiple Diseases 29 Sep 2003 9:33AM $0.610 $0.097 fallen by 84.10%
$6 AGT&SPL ann collaboration to dev new drug therapies 18 Sep 2003 9:51AM $0.590 $0.097 fallen by 83.56%
$6 Preliminary Final Report 10 Sep 2003 5:37PM $0.640 $0.097 fallen by 84.84%

1 - 25 of 29 results

Page 1 of 2

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.